Redhill Biopharma Ltd. (NASDAQ:RDHL) Short Interest Up 166.2% in April

Redhill Biopharma Ltd. (NASDAQ:RDHL) was the recipient of a large increase in short interest in April. As of April 30th, there was short interest totaling 19,071 shares, an increase of 166.2% from the April 15th total of 7,163 shares. Based on an average daily volume of 62,411 shares, the short-interest ratio is presently 0.3 days. Currently, 0.4% of the shares of the stock are sold short.

Hedge Funds Weigh In On Redhill Biopharma

A hedge fund recently bought a new stake in Redhill Biopharma stock. Yorkville Advisors Global LP purchased a new stake in Redhill Biopharma Ltd. (NASDAQ:RDHL) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 386,593 shares of the biotechnology company’s stock, valued at approximately $398,000. Redhill Biopharma accounts for about 0.3% of Yorkville Advisors Global LP’s portfolio, making the stock its 19th largest position. Yorkville Advisors Global LP owned 7.57% of Redhill Biopharma as of its most recent SEC filing. Hedge funds and other institutional investors own 7.20% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings upgraded Redhill Biopharma from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, May 6th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has a consensus rating of “Sell”.

Redhill Biopharma Price Performance

NASDAQ RDHL opened at $1.03 on Friday. Redhill Biopharma has a 1 year low of $0.71 and a 1 year high of $3.31. The company has a market capitalization of $5.35 million, a PE ratio of 0.00 and a beta of 5.05. The company has a fifty day moving average of $0.89 and a two-hundred day moving average of $1.06.

About Redhill Biopharma

RedHill Biopharma Ltd. is a specialty biopharmaceutical company focused on the development and commercialization of proprietary, orally-administered small molecules for the treatment of inflammatory, gastrointestinal and oncology indications. Founded in 2009 and headquartered in Tel Aviv, Israel, RedHill is publicly traded on the Nasdaq under the symbol RDHL. The company’s strategy centers on in-licensing late-stage clinical candidates and advancing them through regulatory review toward global commercialization.

RedHill’s lead marketed product, Talicia® (formerly RHB-105), is an FDA-approved, three-drug treatment for Helicobacter pylori infection, co-commercialized in the United States through a partnership with Bausch Health.